Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements

BACKGROUND: Vedolizumab (VDZ), a humanised monoclonal antibody against a4ß7‐integrin, has shown efficacy in inflammatory bowel disease (IBD). It is of importance to assess the mid‐to long‐term efficacy of VDZ using real‐life data. OBJECTIVE: Our study aimed to determine the efficacy of VDZ in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Mader, Orla, Juillerat, Pascal, Biedermann, Luc, Michetti, Pierre, Hruz, Petr, Pittet, Valerie, Rogler, Gerhard, Zahnd‐Straumann, Nadine, Seibold, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259282/
https://www.ncbi.nlm.nih.gov/pubmed/33203339
http://dx.doi.org/10.1177/2050640620965106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259282/
https://www.ncbi.nlm.nih.gov/pubmed/33203339
http://dx.doi.org/10.1177/2050640620965106

Ejemplares similares